XPH - ETF AI Analysis

Top Page

SPDR S&P Pharmaceuticals ETF (XPH)

Rating:62Neutral

Price Target:―

The SPDR S&P Pharmaceuticals ETF (XPH) has a moderate overall rating, reflecting a mix of strengths and challenges among its holdings. Strong performers like Merck & Company, with its robust financial performance and pipeline advancements, and Eli Lilly, driven by positive earnings sentiment, contribute positively to the ETF's rating. However, weaker holdings such as Nuvation Bio and Terns Pharmaceuticals, both struggling with financial challenges and speculative growth prospects, weigh on the fund's overall score. A key risk factor for this ETF is its exposure to financially unstable companies, which could impact long-term stability.

Positive Factors

Strong Top Holdings

Several top positions, such as Elanco Animal Health and Ligand Pharma, have delivered strong year-to-date performance, boosting the ETF’s returns.

Focused Sector Exposure

The ETF’s heavy allocation to the Health Care sector provides targeted exposure to a resilient and growing industry.

Reasonable Expense Ratio

The fund charges a relatively low expense ratio, making it cost-effective compared to many actively managed funds.

Negative Factors

High Geographic Concentration

The ETF is almost entirely focused on U.S. companies, limiting diversification across global markets.

Underperforming Holdings

Some holdings, like Crinetics Pharmaceuticals, have shown weak year-to-date performance, which could weigh on overall returns.

Sector Over-Concentration

With nearly all assets in Health Care, the ETF is highly exposed to risks specific to this sector, such as regulatory changes or industry downturns.

XPH vs. SPDR S&P 500 ETF (SPY)

AUM235.35M

RegionNorth America

Expense Ratio0.35%

Beta0.73

IssuerSPDR

Inception DateJun 19, 2006

Dividend Yield0.83%

Asset ClassEquity

Index TrackedS&P Pharmaceuticals Select Industry

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume117,395

30 Day Avg. Volume58,974

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

85.47

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering60

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

XPH Summary

The SPDR S&P Pharmaceuticals ETF (XPH) is an investment fund that focuses on the pharmaceutical industry, offering exposure to companies involved in drug development and medical innovations. It includes a mix of large companies like Johnson & Johnson and Eli Lilly, as well as smaller, innovative firms. Investors might consider XPH if they believe in the long-term growth of the health care sector and want to benefit from advancements in biotechnology and increasing global health care needs. However, it’s important to know that this ETF is heavily focused on pharmaceuticals, so its performance can be affected by industry-specific challenges like regulatory changes or slower drug approvals.

How much will it cost me?The SPDR S&P Pharmaceuticals ETF (XPH) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds.

What would affect this ETF?The SPDR S&P Pharmaceuticals ETF (XPH) could benefit from increasing global health care needs, advancements in biotechnology, and demographic trends such as aging populations, which drive demand for innovative drugs and treatments. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, as well as broader economic conditions like rising interest rates that could impact funding for smaller companies in its portfolio. Its focus on U.S.-based pharmaceutical firms makes it sensitive to domestic health care policies and market dynamics.

XPH Top 10 Holdings

The SPDR S&P Pharmaceuticals ETF (XPH) is heavily concentrated in U.S.-based pharmaceutical stocks, with a mix of large-cap leaders and smaller innovators driving its performance. Eli Lilly and Merck provide steady support with their robust financials and promising pipelines, while smaller names like Liquidia Technologies and Crinetics Pharmaceuticals show rising momentum thanks to successful product launches and FDA approvals. However, speculative plays like Nuvation Bio and Terns Pharmaceuticals are lagging, weighed down by financial challenges and cash burn. Overall, the fund leans heavily into health care innovation, but its reliance on smaller, riskier names adds volatility to the mix.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
AXSM	Axsome Therapeutics	2.11%	$4.90M	$8.45B	109.31%	57 Neutral
OGN	Organon	2.10%	$4.89M	$2.09B	-48.71%	53 Neutral
MNMD	Mind Medicine	2.09%	$4.86M	$1.45B	112.12%	40 Neutral
MBX	MBX Biosciences, Inc.	2.08%	$4.84M	$1.38B	124.40%	38 Underperform
NUVB	Nuvation Bio	2.08%	$4.83M	$2.91B	203.96%	45 Neutral
LLY	Eli Lilly & Co	2.06%	$4.78M	$1.03T	35.66%	72 Outperform
MRK	Merck & Company	2.05%	$4.77M	$274.34B	11.83%	80 Outperform
SUPN	Supernus Pharmaceuticals	2.05%	$4.76M	$2.93B	36.49%	55 Neutral
CRNX	Crinetics Pharmaceuticals	2.05%	$4.76M	$5.46B	31.16%	61 Neutral
BMY	Bristol-Myers Squibb	2.04%	$4.75M	$113.80B	0.12%	78 Outperform

XPH Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

53.43

Positive

100DMA

50.39

Positive

200DMA

45.65

Positive

Market Momentum

MACD

0.67

Positive

RSI

56.19

Neutral

STOCH

58.50

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 56.18, equal to the 50-day MA of 53.43, and equal to the 200-day MA of 45.65, indicating a bullish trend. The MACD of 0.67 indicates Positive momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 58.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XPH.

XPH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
XPH	―	―	$235.35M	0.35%	―
FXH	―	―	$980.78M	0.62%	―
IHE	―	―	$952.70M	0.38%	―
RSPH	―	―	$782.03M	0.40%	―
IHF	―	―	$778.41M	0.38%	―
PJP	―	―	$323.66M	0.57%	―

Performance Comparison

XPH

SPDR S&P Pharmaceuticals ETF

56.24

13.19

30.64%

FXH

First Trust Health Care AlphaDEX Fund

―

IHE

iShares U.S. Pharmaceuticals ETF

―

RSPH

Invesco S&P 500 Equal Weight Health Care ETF

―

IHF

iShares U.S. Healthcare Providers ETF

―

PJP

Invesco Dynamic Pharmaceuticals ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents